ClinicalTrials.Veeva

Menu
S

SMS Clinical Research | Mesquite, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Amlitelimab
SCD-044
RO7790121
ESK-001
PF-07321332
Ritonavir
Olezarsen
TCK-276
NTZ
Pimodivir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 50 total trials

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men...

Active, not recruiting
Hypogonadism
Drug: Jatenzo

This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called...

Active, not recruiting
Schizophrenia
Device: Digital therapeutic (CT-155)

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for athero...

Enrolling
Diabetes Mellitus, Type 2
Metabolic Syndrome
Device: The Cleerly CAD Staging System

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Active, not recruiting
Plaque Psoriasis
Drug: ESK-001
Drug: Placebo

The purpose of the study is to evaluate the reactogenicity, safety, and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccin...

Active, not recruiting
Respiratory Syncytial Virus
Biological: Placebo
Biological: mRNA-1345

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) co...

Enrolling
Moderately to Severely Active Ulcerative Colitis
Drug: Afimkibart
Drug: Placebo

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance...

Enrolling
Moderately to Severely Active Crohns Disease
Drug: Placebo
Drug: Afimkibart

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participant...

Active, not recruiting
Dermatitis Atopic
Drug: Topical calcineurin inhibitors
Drug: Amlitelimab

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together.This study is seeking healthy...

Enrolling
COVID-19 (Coronavirus Disease 2019)
Influenza
Biological: Licensed Influenza Vaccine 2
Biological: Licensed Influenza Vaccine 1

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate t...

Enrolling
Dermatitis Atopic
Drug: Oral corticosteroids
Drug: Amlitelimab

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-fr...

Enrolling
Gastroesophageal Reflux
Drug: MHS-1031
Other: Placebo

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Active, not recruiting
Lower Respiratory Tract Illness
Biological: RSVpreF
Biological: Placebo

This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.

Active, not recruiting
Moderate to Severe Plaque Psoriasis
Drug: Placebo
Drug: SCD-044_Dose 3

Trial sponsors

Pfizer logo
BioNTech logo
Janssen (J&J Innovative Medicine) logo
Sanofi logo
A
Boehringer Ingelheim logo
Enanta Pharmaceuticals logo
Gilead Sciences logo
Ionis Pharmaceuticals logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems